A nucleosidic medicine, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine [3′-ethynylcytidine (ECyd)], is a potent inhibitor of RNA polymerase I and shows anticancer activity to various human solid tumors in vitro and in vivo. ECyd is phosphorylated to 3′-ethyntlcytidine 5′-monophosphate by uridine/cytidine kinase 2 (UCK2) and subsequently further to diphosphate and triphosphate (3′-ethyntlcytidine 5′-diphosphate, 3′-ethyntlcytidine 5′-triphosphate). 3′-Ethyntlcytidine 5′-triphosphate is an active metabolite that can inhibit RNA polymerase I competitively, causing cancer cell death. Here, to identify the UCK2 mutation for detecting responder or nonresponder to ECyd, we investigated the relationship between point mutation of the UCK2 gene and response to ECyd in various human solid tumors. We identified several functional point mutations including the splice-site mutation of the UCK2 gene IVS5+5 G>A. In addition, we found that the IVS5+5 G>A variant generates an aberrant mRNA transcript, namely, truncated mRNA was produced and normal mRNA levels were markedly decreased in the ECyd-resistant cancer cell line HT1080. We concluded that these findings strongly suggest that the IVS5+5 G>A variant would affect the expression level of the UCK2 transcript, resulting in decreased sensitivity to ECyd.
aDivision of International Infectious Diseases Control, Okayama University, Okayama
bDepartment of Biochemistry, Tokyo University of Science, Chiba
cCenter for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Hokkaido, Japan
Correspondence to Akira Sato, PhD, Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan Tel: +81 471 241 501; fax: +81 471 213 620; e-mail: email@example.com
Correspondence to Hye-Sook Kim, PhD, Division of International Infectious Diseases Control, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-Ku, Okayama, Okayama 700-8530, Japan Tel/fax: +81 862 517 975; e-mail: firstname.lastname@example.org
Received March 21, 2017
Accepted April 29, 2017